By Anthony O. Goriainoff

 

AstraZeneca PLC said Tuesday that the U.S. Food and Drug Administration approved Farxiga for the treatment of chronic kidney disease in patients at risk of progression with, and without, Type 2 diabetes.

The London-listed pharmaceutical company said the sodium-glucose cotransporter 2 inhibitor's approval was based on positive results from the DAPA-CKD Phase III trial.

The company said Farxiga will be used to decrease the risk of end-stage kidney disease, cardiovascular death, as well as hospitalization for heart failure in adults with chronic kidney disease at risk of progression, among others.

 

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

 

(END) Dow Jones Newswires

May 04, 2021 02:33 ET (06:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.